Instrument Inactif

Communiqués Sprint Bioscience AB Nasdaq Stockholm

Actions

Cours en clôture Nasdaq Stockholm Autres places de cotation
-	-

08/05	Sprint Bioscience AB (publ) annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
14/02	Sprint Bioscience AB (publ) annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI

Sprint Bioscience - Improved sales and activity	10/05	AQ
Positive preclinical results in Sprint Bioscience's oncology program targeting TREX1	11/04	AQ
New data from the VPS34 program published	20/03	AQ
Sprint Bioscience participates in a delegation trip to Washington DC	08/03	AQ
Sprint Bioscience Q4 2023 - A major step towards break-even	15/02	AQ
Sprint Bioscience’s DISA program further validated in two recent scientific publications	22/01	AQ
Sprint Bioscience - Replacing Decipher as a VPS34 partner	02/01	AQ
Sprint Bioscience - Easing pressure and a sharper focus on value drivers	20/11	AQ
Sprint Bioscience - New beginnings	13/09/23	AQ
Sprint Bioscience licenses the VADA (VRK1) program to Day One Biopharmaceuticals	16/08/23	AQ
Sprint Bioscience Q1 2023 - VADA deal needed	11/05/23	AQ
Sprint Bioscience presents preclinical data from the DISA program at research conference	02/05/23	AQ
Sprint Bioscience Q4 2022 - Temporary setbacks	16/02/23	AQ
Sprint Bioscience reports novel AML target proteins in ongoing collaboration	08/11/22	AQ
BioStock: Sprint Bioscience focuses on developing internal programs and partnering	27/10/22	AQ
Sprint Bioscience Q3 2022 - Seal the deal	26/10/22	AQ
BioStock: Sprint Bioscience increases innovation power	17/05/22	AQ
Sprint Bioscience expands collaboration to identify new target proteins	13/05/22	AQ
BioStock: Sprint Bioscience maintains focus on developing the portfolio	12/05/22	AQ
Sprint Bioscience appoints Scientific Advisory Board	11/05/22	AQ

Aucun résultat pour cette recherche